Dr. Rocha Lima is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Wake Forest Baptist Medical Center
Division of Hematology and Oncology
Winston Salem, NC 27157Phone+1 336-713-5440Fax+1 336-713-5445
Education & Training
Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 1995 - 1997
Federal University of Bahia Faculty of MedicineClass of 1989
Certifications & Licensure
FL State Medical License 2002 - 2026
NC State Medical License 2017 - 2025
SC State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 61 citationsA Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcin...Philip A. Philip, Marc Buyse, Angela T. Alistar, Caio M.S.R. Lima, Sanjeev Luther
Future Oncology. 2019-09-12 - 10 citationsThe nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma.Sofia Palacio, Peter J. Hosein, Isildinha M. Reis, Ikechukwu Immanuel Akunyili, Vinicius Ernani
Journal of Gastrointestinal Oncology. 2018-02-01 - 14 citationsPhase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment.Richard Kim, E. Gabriela Chiorean, Manik Amin, Caio Rocha-Lima, Jitendra Gandhi
British Journal of Cancer. 2017-06-20
Lectures
- A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of p...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- A phase I clinical trial of fluorouracil (5-FU) + devimistat (CPI-613) combination in previously treated patients (pts) with metastatic colorectal cancer (MCR).2019 ASCO Annual Meeting - 6/1/2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
